BMS bags EC approval of Camzyos

Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has approved Camzyos (mavacamten) to treat symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM).

Camzyos is the first and only allosteric and reversible inhibitor selective for cardiac myosin approved in all European Union (EU) member states, and is the first cardiac myosin inhibitor that targets the underlying pathophysiology of HCM.

Samit Hirawat, chief medical officer of the US drug major, said: “This approval marks an important milestone for patients in Europe who will now have a therapeutic option in Camzyos, a first-in-class cardiac myosin inhibitor that treats the underlying pathophysiology of symptomatic obstructive HCM.